UCB unveils new R&D partnership with Oxford University | UCB
UCB's Global Corporate Website

UCB unveils new R&D partnership with Oxford University

Posted by
Scott Fleming, UK Communications
We have recently announced a new collaboration with Oxford University to develop innovative research in immunology and neurology.

The partnership will see UCB contribute £3.6 million (€4.3 million) over three years and gives scientists from our company and from Oxford University a chance to work together to find treatments for serious diseases. We expect this collaboration to be even greater than the sum of its parts.

Teaming up with one of the world’s oldest and most prestigious universities combines our own world-class antibody research with Oxford’s academic excellence, and applies it to finding new solutions for patients.

This new alliance has not happened in isolation. Regular readers will be aware of UCB’s commitment to R&D partnerships. For example, last year UCB joined forces with Harvard University to boost innovative research and drug discovery.

More recently, our CEO, Dr Roch Doliveux, has been appointed to chair the Innovative Medicines Initiative (IMI) which is a major public-private partnership co-funded by industry and the European Union.

We’ve even worked with Amgen and NASA on a truly out-of-this-world project.

For all of us at UCB, partnerships with other companies, with academic and with patient groups are a source of pride as well as living demonstration of our commitment to open innovation.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.
1 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.